These data underscore the dual role of S-nitrosylation as both a driver of oncogenic signaling and a suppressor of anti-tumor immunity, identifying it as a critical, non-genetic contributor to therapeutic resistance in NRAS-mutant melanoma. Here, NRAS is linked to melanoma.